EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Potential Impact of Slowing Disease Progression in Early Symptomatic Alzheimer’s Disease on Patient Quality of Life, Caregiver Time, and Total Societal Costs: Estimates Based on Findings from GERAS-US Study

Julie M Chandler, Wenyu Ye, Xiaojuan Mi, Erin G Doty, Joseph A Johnston

Journal of Alzheimer's Disease · 16.07.2024 · 100 (2) · 563-578

DOI: 10.3233/jad-231166 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Alzheimer's Disease, erschienen am 16.07.2024. Verfasst von Julie M Chandler und 4 weiteren Autor:innen. Beteiligte Einrichtung: Eli Lilly and Company, Indianapolis, IN, USA. Hauptthemen laut MEDLINE: Alzheimer Disease, Quality of Life, Disease Progression, Caregivers. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Impact of Alzheimer’s disease (AD) progression on patient health-related quality of life (HRQoL), caregiver time, and societal costs is not well characterized in early AD.

Objective

To assess the association of change in cognition with HRQoL, caregiver time, and societal costs over 36 months, and estimate the impact of slowing disease progression on these outcomes.

Methods

This post-hoc analysis included patients with amyloid-positive mild cognitive impairment (MCI) and mild AD dementia (MILD AD) from the 36-month GERAS-US study. Disease progression was assessed using the Mini-Mental State Examination score. Change in outcomes associated with slowing AD progression was estimated using coefficients from generalized linear models.

Results

At baseline, 300 patients had MCI and 317 had MILD AD. Observed natural progression over 36 months was associated with: 5.1 point decline in the Bath Assessment of Subjective Quality of Life in Dementia (BASQID) score (for HRQoL), increase in 1,050 hours of total caregiver time, and $8,504 total societal costs for MCI; 6.6 point decline in the BASQID score, increase in 1,929 hours of total caregiver time, and $12,795 total societal costs for MILD AD per person. Slowing AD progression by 30% could result in per person savings in HRQoL decline, total caregiver time, and total societal costs: for MCI: 1.5 points, 315 hours, and $2,638; for MILD AD: 2.0 points, 579 hours, and $3,974.

Conclusions

Slowing AD progression over 36 months could slow decline in HRQoL and save caregiver time and societal cost in patients with MCI and MILD AD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alzheimer DiseaseQuality of LifeDisease ProgressionCaregiversCost of IllnessCognitive DysfunctionHumansMaleFemaleAgedAged, 80 and overUnited StatesMental Status and Dementia Tests

Stichwörter der Autor:innen

Alzheimer’s diseasePET scanamyloidburden of illnesscost of illnessdementiaeconomic burdenhealth-related quality of lifehealthcare costsmild cognitive impairment

Autor:innen und Institutionen

  • Eli Lilly and Company, Indianapolis, IN, USA.
  • TechData Services Company, King of Prussia, PA, USA.

Zitieren

APA

Chandler, J. M., Ye, W., Mi, X., Doty, E. G., & Johnston, J. A. (2024). Potential Impact of Slowing Disease Progression in Early Symptomatic Alzheimer’s Disease on Patient Quality of Life, Caregiver Time, and Total Societal Costs: Estimates Based on Findings from GERAS-US Study. Journal of Alzheimer's Disease, 100(2), 563-578. https://doi.org/10.3233/jad-231166

Vancouver

Chandler JM, Ye W, Mi X, Doty EG, Johnston JA. Potential Impact of Slowing Disease Progression in Early Symptomatic Alzheimer’s Disease on Patient Quality of Life, Caregiver Time, and Total Societal Costs: Estimates Based on Findings from GERAS-US Study. Journal of Alzheimer's Disease. 2024;100(2):563-578. doi:10.3233/jad-231166

BibTeX
@article{Chandler2024,
  author = {Chandler, Julie M and Ye, Wenyu and Mi, Xiaojuan and Doty, Erin G and Johnston, Joseph A},
  title = {Potential Impact of Slowing Disease Progression in Early Symptomatic Alzheimer’s Disease on Patient Quality of Life, Caregiver Time, and Total Societal Costs: Estimates Based on Findings from GERAS-US Study},
  journal = {Journal of Alzheimer's Disease},
  year = {2024},
  volume = {100},
  number = {2},
  pages = {563--578},
  doi = {10.3233/jad-231166}
}
Kostenlos starten →